ClinicalTrials.gg
CompletedNCT07787728Updated Oct 28, 2026

Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or Obesity

A Phase 1 interventional study of MWN109 1 and MWN109 2 in Overweight , Obesity, sponsored by Shanghai Minwei Biotechnology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Minwei Biotechnology Co., Ltd (part of Lepu Medical) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jul 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Obesity by Lepu Medical — 6 open to participants now, 8 under way, 1 of them phase 3. Obesity · Lepu Medical.

Enrollment
13th of 14
40 · median 88
Started
2025
with 5 others
Phase 1
8 of 14
5 open now
Registered
5th of 14
by date

Among the 14 studies in Obesity by Lepu Medical, this one is the 13th largest by enrollment, is one of 6 that started in 2025, is one of 8 in phase 1, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

6 of the 14 studies in Obesity by Lepu Medical are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Obesity by Lepu Medical, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, multiple-dose phase Ib clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity characteristics of MWN109 injection in Chinese non-diabetic participants with overweight or obesity.

A total of 40 participants were enrolled in the study. All participants were stratified and randomized by gender, and randomly assigned to 4 dose groups at a ratio of 1:1:1:1, with 10 participants in each group(8 participants received MWN109 injection, and 2 received placebo). Each treatment group will use a dose titration method to reach the target dose.

The study includes a maximum screening period of up to 2 weeks, a 14-week treatment period and a 2-week follow-up period, totaling 18 weeks. The primary endpoint is the incidence of adverse events. The secondary endpoint is the pharmacokinetic characteristics.

03

Conditions studied

  • Overweight , Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 40 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.

First submitted after Shanghai Minwei Biotechnology Co., Ltd became part of Lepu Medical.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female individuals aged between 18 and 65 years old (inclusive of 18 and 65 years old), as determined by the date of signing the form.
  2. Weight ≥ 70 kg (for males) or ≥ 60 kg (for females), with a ranging from 27.0 to 35.0 kg/m2.
  3. Resting heart rate ≥ 55 beats per minute and ≤ 90 beats per minute (results of 12-lead before randomization).
  4. Self-reported or documented weight change before the screening period of 12 weeks was less than 5.0%, and the participant can maintain their original diet and lifestyle during the trial period.
  5. Participants must have no pregnancy plans from the time of signing the informed consent form until 4 months after the last dose of the drug.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with a known allergy to GLP - 1 receptor agonist drugs or the components of MWN109 injection, or those with severe allergic diseases or a severe allergic constitution at the time of screening.
  2. Used GLP-1 receptor agonists or similar drugs targeting the same site, drugs that affect body weight, or weight-loss drugs within 12 weeks before screening.
  3. Laboratory abnormalities: ≥ 6.5%, or fasting blood glucose ≥ 7.0 mmol/L, or 2-hour blood glucose in the OGTT≥ 11.1 mmol/L (participants with fasting blood glucose between 6.1 and 6.9 mmol/L at the time of screening need to undergo the OGTT), or AST ≥ 2.5ULN, or total serum ≥ 1.5ULN. Serum amylase or serum lipase ≥ 1.5ULN. \< 60 mL/min/1.73 m². Serum calcitonin level ≥ 35 ng/L (pg/mL). TSH> 6.0 mIU/L or \< 0.4 mIU/L. Triglycerides ≥ 5.64 mmol/L (500 mg/dL). HGB\< 110 g/L (for males) or \< 100 g/L (for females).
  4. shows second- or third-degree atrioventricular block, long syndrome (QTcF > 470 ms for females or > 450 ms for males), pre-excitation syndrome, or other ECG abnormalities that the investigator deems require drug intervention.
  5. Participants with a history or evidence of any of the following diseases:

    • Obesity secondary to other diseases or drug use.
    • Previously or currently diagnosed with type 1 or type 2 diabetes at the time of screening.
    • Previously or currently diagnosed with acute or chronic pancreatitis, or pancreatic injury at the time of screening;.
    • Previous diagnosis of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2A or 2B, or with a relevant family history.
    • Previously undergone gastric weight-loss surgery, or planning to undergo weight-loss surgery, liposuction, or abdominal fat-reduction surgery during the study, which can significantly affect body weight.
    • A history of past or current depression, other severe mental illnesses, or a history of suicidal tendencies or behaviors.
    • Diagnosed with a malignant tumor within 5 years before screening (except for cured carcinoma in situ), or with a potential malignant tumor as evaluated at the time of screening.
    • A history of any of the following heart diseases within 6 months before screening.
    • Suffered from hemorrhagic or ischemic stroke within 6 months before screening and deemed ineligible to participate in this clinical trial by the investigator.
    • Experienced severe hypoglycemia or recurrent (≥ 2 times within 6 months) symptomatic hypoglycemia within 6 months before screening.
    • Participants with uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at the time of screening) after treatment, or those with untreated blood pressure reaching the above-mentioned criteria at the time of screening.
    • Abnormal thyroid function that cannot be controlled with a stable drug dosage at the time of screening, or abnormal thyroid function test results with clinical significance that require initiation of treatment at the time of screening.
    • Abdominal ultrasound at the time of screening indicates symptomatic gallbladder polyps or other gallbladder diseases that require treatment, or gallbladder diseases with symptoms that the investigator deems require treatment.
    • gastric emptying abnormalities, gastric reflux disease, active gastrointestinal diseases, etc., present at the time of screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    MWN109 Cohort 1

    Drug: MWN109 1

  • Experimental
    MWN109 Cohort 2

    Drug: MWN109 2

  • Experimental
    MWN109 Cohort 3

    Drug: MWN109 3

  • Experimental
    MWN109 Cohort 4

    Drug: MWN109 4

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered SC, QW, 14 weeks

  • Administered SC, QW, 14 weeks

  • Administered SC, QW, 14 weeks

  • Administered SC, QW, 14 weeks

  • DrugPlacebo

    Administered SC, QW, 14 weeks

07

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Safety and tolerability assessed by the incidence of AEs and SAEs.

    Time frame: From Day 1 to Day 113

Secondary outcomes

  1. Maximum Concentration (Cmax)

    Cmax of MWN109.

    Time frame: From Day 1 to Day 60

  2. Time to Reach Maximum Concentration (Tmax)

    Tmax of MWN109.

    Time frame: From Day 1 to Day 60

  3. Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t)

    AUC0-t of MWN109.

    Time frame: From Day 1 to Day 60

  4. Area Under the Curve From Time 0 to Infinity (AUC0-inf)

    AUC0-inf of MWN109.

    Time frame: From Day 1 to Day 60

  5. Elimination Half-Life (t1/2)

    t1/2 of MWN109.

    Time frame: From Day 1 to Day 60

  6. Steady State Maximum Concentration (Cmax,ss)

    Cmax,ss of MWN109.

    Time frame: From Day 1 to Day 113

  7. Steady State Minimum Concentration (Cmin,ss)

    Cmin,ss of MWN109.

    Time frame: From Day 1 to Day 113

  8. Steady State Concentration (Cav,ss)

    Cav,ss of MWN109.

    Time frame: From Day 1 to Day 113

  9. Time to Reach Maximum Concentration at Steady State (Tmax,ss)

    Tmax,ss of MWN109.

    Time frame: From Day 1 to Day 113

  10. Steady State Apparent Terminal Elimination Half-life (t1/2,ss)

    t1/2,ss of MWN109.

    Time frame: From Day 1 to Day 113

  11. Area Under Concentration-time Profiles during a Dose Interval (AUC0-τ,ss)

    AUC0-τ,ss of MWN109.

    Time frame: From Day 1 to Day 113

  12. Steady State Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t,ss)

    AUC0-t,ss of MWN109.

    Time frame: From Day 1 to Day 113

08

Study locations

1 site
  • The First Affiliated Hospital of Yunnan University of Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine)
    Kunming, Yunnan, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 5 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Aug 26, 2026
StartActual
Jul 14, 2025
Primary completionActual
Dec 16, 2025
CompletionActual
Dec 16, 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
1 update, last Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Minor edits only
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07787728
Responsible party
Sponsor
First posted
Aug 26, 2026
Start date
Jul 14, 2025
Primary completion
Dec 16, 2025
Completion
Dec 16, 2025
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MWN109

Start the discussion